Q-omics provides the consensus-scored CHORDC1P1 profile across patient tissues and cancer cell-line models. CHORDC1P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, CHORDC1P1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, CHORDC1P1 RNA expression shows 16,025 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SARC, LIHC, and THYM as cancer lineages where CHORDC1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHORDC1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHORDC1P1 survival associations across molecular data types. CHORDC1P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHORDC1P1 RNA expression–survival associations across cancer types. High CHORDC1P1 expression shows unfavorable associations in UVM, PAAD and THCA, but favorable associations in SARC, BRCA and CHOL. The SARC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SARC as the clearest survival context for CHORDC1P1 RNA expression.
This table summarizes CHORDC1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CHORDC1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHORDC1P1 shows lower tumor expression in UCEC, THCA, KICH and BRCA and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher CHORDC1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.135, t-test p < 0.001).
This table shows molecular features associated with CHORDC1P1 in patient tissues and cancer cell lines. In patient samples, CHORDC1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
